Hepatitis C Virus and the Humoral Immune System
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.
| Condition |
|---|
|
Hepatitis C Virus |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Hepatitis C Virus and the Humoral Immune System |
- Define the relationships between HCV infection, B cell phenotype, and B cell function [ Time Frame: 5 years ] [ Designated as safety issue: No ]Define the relationships between HCV infection, B cell phenotype, and B cell function
Biospecimen Retention: Samples With DNA
whole blood
| Estimated Enrollment: | 810 |
| Study Start Date: | September 2001 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
HCV infection
current HCV infection, including intravenous drug users
|
|
cryoglobulinemia
cryoglobulinemia and without HCV infection
|
|
chronic liver disease
chronic liver disease not due to hepatitis C virus infection
|
|
Sustained Virologic responders
successfully treated for HCV infection
|
|
normal
normal, healthy volunteers
|
Detailed Description:
The long-term goal of our research is to understand why immune complexes (ICs) are produced in patients infected with HCV, and whether these complexes affect virus interaction with target cells. We have found that many patients infected with HCV have an increased frequency of circulating B cells, but no evidence that the increased B cells are activated of proliferating. One possible mechanism for such an increase would be a change in levels of chemokines that influence B cell localization and trafficking. Our studies are aimed at testing the following hypotheses:
- One hypothesis is that HCV infection results in increased levels of specific cytokines and chemokines that may affect the motility and localization of immature and mature B cells. An alternative model is that HCV infection leads to chronic antigenic stimulation of B lymphocytes, and that the abnormalities of B cell function associated with HCV infection reflect this chronic antigenic stimulation.
- A second hypothesis is that autoantibodies and immune complexes present in HCV patient serum contribute to the persistence and spread of viral infection.
To test these hypotheses, we are measuring levels of chemokines, the frequency of circulating B cells (mature resting B cells, mature activated B cells, memory B cells, and immature B cells), and the levels and components of ICs in the blood of HCV-infected patients. Controls include healthy volunteers and patients with chronic liver disease unrelated to HCV infection. No interventions in patient care are planned. When patients elect to undergo standard antiviral therapies under the supervision of their hepatologists, we will study the outcomes of therapy (no virologic response, partial or transient virologic response, sustained virologic response) to determine whether any of the observed alterations in chemokine levels, B cell frequency or activation, or immune complex levels correlate with the patient's response to antiviral therapy.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
primary care clinics of doctors at NYPH and the NYC metropolitan area
Inclusion Criteria:
- Healthy volunteers, no liver disease
- Chronic infection with hepatitis C virus
- Other chronic liver disease unrelated to hepatitis C virus
- Subjects in all groups must have sufficiently healthy veins to allow blood collection.
Exclusion Criteria:
- Any medical condition that, in the opinion of the investigators, precludes the patient's participation
Contacts and Locations| Contact: Lynn B Dustin, PHD | 800-782-2737 |
| United States, New York | |
| Rockefeller University Hosital | Recruiting |
| New York, New York, United States, 10021 | |
| Contact: Caroline Melendez 800-782-2737 | |
| Principal Investigator: Lynn B Dustin, PHD | |
| Principal Investigator: | Lynn B Dustin, PHD | Rockefeller University |
More Information
No publications provided
| Responsible Party: | Rockefeller University |
| ClinicalTrials.gov Identifier: | NCT00219999 History of Changes |
| Other Study ID Numbers: | LDU-0437, R01AI60561 |
| Study First Received: | September 19, 2005 |
| Last Updated: | December 4, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Rockefeller University:
|
Hepatitis Hepacivirus B Lymphocytes Chemokines Antibodies |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis C Hepatitis, Viral, Human Virus Diseases Liver Diseases |
Digestive System Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 19, 2013